NEW

Johnson & Johnson to Acquire Shockwave Medical

Johnson & Johnson and Shockwave Medical, Inc. today announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share in cash, corresponding to an enterprise value of...

Medline Expands Catheter Portfolio

Medline and Consure Medical have announced a new agreement for Medline to exclusively distribute the QiVi MEC male external urine management device to help guard against catheter-associated urinary tract infections (CAUTI) and incontinence-associated dermatitis (IAD)....

FDA Clears Single-use Flexible Ureteroscope

Olympus, a global medical technology company committed to making people's lives healthier, safer and more fulfilling, announced U.S. FDA 510(k) clearance of its first single-use ureteroscope system, RenaFlex™, with full market availability to be announced at a later...

Brainlab, Fujifilm Offer Advanced Neurosurgery Capabilities

FUJIFILM Healthcare Americas Corporation and Brainlab recently announced that Brainlab will be the exclusive U.S. distributor of ARIETTA Precision Ultrasound for neurosurgery applications to be utilized with Brainlab’s surgical navigation systems. ARIETTA Precision,...

Minerva Surgical Launches Uterine Care Kit

Minerva Surgical announced today the launch of a complete suite of minimally invasive devices and website to support health care practitioners in treating Abnormal Uterine Bleeding (AUB). One-third of outpatient visits to the gynecologist are for AUB, and AUB accounts for more than 70% of all gynecologic consults in the perimenopausal and post-menopausal years[1]. This common condition often results in a hysterectomy due to benign causes if not treated.

Hysterectomy is the second most common surgery performed on reproductive-age women in the U.S., after cesarean section. Nearly 68% of the 400,000 hysterectomies performed each year are due to benign conditions that involve abnormal uterine bleeding, uterine fibroids and endometriosis[2].

The conservatively estimated annual costs of AUB were approximately $1 billion direct costs to women and $12 billion indirect costs to the community[1].

“AUB holds women hostage. Their personal and professional quality of life suffers significantly, and the financial burden is crushing,” said Dave Clapper, president & CEO, Minerva Surgical. “Our best-in-class devices are a leap forward in treatment, but we also commit to elevate awareness of AUB in our communities. We are excited to do our part to eliminate this horrible condition that too often results in unnecessary hysterectomies.”

Minerva Surgical, is comprised of a newly minted suite of minimally invasive tools: the Minerva Endometrial Ablation System, the fastest growing endometrial ablation product, Symphion, the all-in-one tissue removal system that transforms the way physicians remove uterine fibroids, Genesys HTA Endometrial Ablation System, trusted for decades by physicians desiring visualization within the uterine cavity during treatment, and the Resectr device for the removal of endometrial polyps in the medical office setting.

“Health care practitioners and their patients are benefiting from these minimally invasive devices that drive down the cost of care for AUB. And now we can help them even more with a website that serves as an on-demand tool for AUB treatment and awareness information,” said Tom Pendlebury, vice president of sales and marketing, Minerva Surgical.

Visit the new health care practitioner website at www.minervasurgical.com.

[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7291434/#CR1

[2] Plotting the Downward Trend in Traditional Hysterectomy

Previous

Next

Submit a Comment

Your email address will not be published. Required fields are marked *

X